Observational
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Otitis Media
Conditions
Otitis Media
Trial Timeline
Sep 1, 2010 → Jan 1, 2016
NCT ID
NCT01199016About Observational
Observational is a pre-clinical stage product being developed by Pfizer for Otitis Media. The current trial status is completed. This product is registered under clinical trial identifier NCT01199016. Target conditions include Otitis Media.
What happened to similar drugs?
2 of 12 similar drugs in Otitis Media were approved
Approved (2) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01199016 | Pre-clinical | Completed |
Competing Products
15 competing products in Otitis Media
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1% + piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1% + piperacillin 2% + tazobactam 0.25% + piperacillin 4% + tazobactam 0.5% + piperacillin 8% + tazobactam 1.0% | Yuhan | Phase 1/2 | 24 |
| ofloxacin otic solution 0.3% | Daiichi Sankyo | Phase 3 | 40 |
| levofloxacin | Johnson & Johnson | Phase 3 | 40 |
| levofloxacin; amoxicillin/clavulanate | Johnson & Johnson | Phase 3 | 40 |
| V114 | Merck | Phase 3 | 40 |
| Montelukast + Placebo | Merck | Approved | 43 |
| 7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccine | Merck | Phase 3 | 40 |
| Prevenar | Pfizer | Pre-clinical | 26 |
| Zmax | Pfizer | Phase 3 | 40 |
| Saline + Fentanyl + Dexmedetomidine + Dexmedetomidine | Pfizer | Approved | 43 |
| amoxicillin/clavulanate postassium (Augmentin ES-600) + azithromycin SR | Pfizer | Phase 3 | 40 |
| 60 mg/kg azithromycin ER + 30 mg/kg azithromycin IR | Pfizer | Phase 2 | 35 |
| Telithromycin (HMR3647) | Sanofi | Phase 3 | 40 |
| telithromycin (HMR3647) | Sanofi | Phase 3 | 32 |
| Telithromycin + Azithromycin | Sanofi | Phase 3 | 32 |